SCHEMBL2018075

SCHEMBL2018075

CC(=O)c1cc(Cl)c(C)c(C#N)c1O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.35
KDM4E B2RXH2 4/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
MAPT P10636 4/20 0.34
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.34
NSD2 O96028 1/20 0.34
POLB P06746 1/20 0.34
MCL1 Q07820 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
UPP1 Q16831 1/20 0.33
SCN9A Q15858 1/20 0.33
ALDH1A1 P00352 3/20 0.33
GAA P10253 2/20 0.33
TTR P02766 1/20 0.32
ALB P02768 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
MAPK1 P28482 2/20 0.32
DHODH Q02127 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18265680 0.83 NOTUM (0.35) NOTUMKDM4ESMN1; SMN2MAPTKMT2A
SCHEMBL15283183 0.79 TTR (0.39) NOTUMKDM4ESMN1; SMN2MAPTKMT2A
SCHEMBL14753933 0.78 MEN1 (0.40) KDM4ESMN1; SMN2MAPTKMT2AMEN1
SCHEMBL9929066 0.75 GAA (0.36) NOTUMKDM4ESMN1; SMN2MAPTPOLB
SCHEMBL9928731 0.74 MEN1 (0.37) KDM4ESMN1; SMN2MAPTKMT2AMEN1
SCHEMBL2011953 0.74 MEN1 (0.37) KDM4ESMN1; SMN2MAPTKMT2AMEN1
SCHEMBL12631710 0.74 GRIN2D (0.38) KDM4ESMN1; SMN2MAPTKMT2AMEN1
SCHEMBL20254619 0.72 MEN1 (0.41) KDM4ESMN1; SMN2MAPTKMT2AMEN1
SCHEMBL2014204 0.71 PIK3CD (0.44) NOTUMKDM4EKMT2AALDH1A1GAA
SCHEMBL2033210 0.71 HSD11B1 (0.37) NOTUMSCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250325550-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS INCYTE CORP (US) 2025-10-23 US disclosed
US-20250129098-A1 BICYCLIC HETEROARYLAMINOALKYL PHENYL DERIVATIVES AS PI3K INHIBITORS INCYTE HOLDINGS CORPORATION 2025-04-24 US disclosed
EP-3888657-B1 HETEROCYCLYLAMINES AS PI3K INHIBITORS INCYTE HOLDINGS CORP (US) 2025-03-19 EP disclosed
US-12201636-B2 Heterocyclylamines as PI3K inhibitors INCYTE CORPORATION (US) 2025-01-21 US disclosed
US-20240216377-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS INCYTE CORPORATION 2024-07-04 US disclosed
US-20240216377-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS INCYTE CORPORATION 2024-07-04 US disclosed
US-20240216377-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS INCYTE CORPORATION 2024-07-04 US disclosed
US-11999751-B2 Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors INCYTE CORPORATION (US) 2024-06-04 US disclosed
US-11819505-B2 Heterocyclylamines as PI3K inhibitors INCYTE CORPORATION (US) 2023-11-21 US disclosed
US-11819505-B2 Heterocyclylamines as PI3K inhibitors INCYTE CORPORATION (US) 2023-11-21 US disclosed
WO-2013033569-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS INCYTE CORPORATION (US) 2013-03-07 WO disclosed
WO-2013033569-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS INCYTE CORPORATION (US) 2013-03-07 WO disclosed
WO-2012087881-A1 N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS INCYTE CORPORATION (US) 2012-06-28 WO disclosed
US-20120157430-A1 N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS INCYTE CORPORATION 2012-06-21 US disclosed
US-20120157430-A1 N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS INCYTE CORPORATION 2012-06-21 US disclosed
US-20120157430-A1 N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS INCYTE CORPORATION 2012-06-21 US disclosed
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION 2011-07-28 US disclosed
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION 2011-07-28 US disclosed
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION 2011-07-28 US disclosed
WO-2011075630-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250325550-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS PIK3CA, PIK3CD, PIK3CB NOTUM 4072/4885KDM4E 916/4885SMN1; SMN2 4552/4885
US-20120157430-A1 N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS PIK3CA, PIK3CD, PI4KB NOTUM 4134/4885KDM4E 1582/4885SMN1; SMN2 2711/4885
US-11999751-B2 Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors PIK3CA, PIK3CD, PIK3R1 NOTUM 2957/4885KDM4E 1871/4885SMN1; SMN2 4294/4885
US-20240216377-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS PIK3CA, PIK3CD, PIK3CB NOTUM 4072/4885KDM4E 916/4885SMN1; SMN2 4552/4885
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS PIK3R1, PIK3R3, PIK3R2 NOTUM 3968/4885KDM4E 1058/4885SMN1; SMN2 4640/4885
US-11819505-B2 Heterocyclylamines as PI3K inhibitors PIK3CA, PIK3CD, PIK3CB NOTUM 4072/4885KDM4E 916/4885SMN1; SMN2 4552/4885
US-20250129098-A1 BICYCLIC HETEROARYLAMINOALKYL PHENYL DERIVATIVES AS PI3K INHIBITORS PIK3CA, PIK3CD, PIK3R1 NOTUM 2957/4885KDM4E 1871/4885SMN1; SMN2 4294/4885
US-12201636-B2 Heterocyclylamines as PI3K inhibitors PIK3CA, PIK3CD, PIK3CB NOTUM 4072/4885KDM4E 916/4885SMN1; SMN2 4552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.